CAJ | 학술논문

目的评价恩替卡韦抗病毒的疗效并分析其预测因素。方法61例慢性乙型肝炎患者接受恩替卡韦抗病毒治疗48周，分别于基线、4、12、24和48周检测患者肝功能、HBV 血清标志物、HBV DNA 定量。结果治疗48周时 ALT 复常率和 HBV DNA 转阴率分别达95．1％和91．8％，HBsAg 定量较基线显著下降（P ＜0．05）；48周时完全病毒学应答率与第4周时 HBV DNA 载量有显著相关性。结论恩替卡韦抗病毒安全、有效；第4周时 HBV DNA 载量对48周时完全病毒学应答率有很好的预测作用。
목적평개은체잡위항병독적료효병분석기예측인소。방법61례만성을형간염환자접수은체잡위항병독치료48주，분별우기선、4、12、24화48주검측환자간공능、HBV 혈청표지물、HBV DNA 정량。결과치료48주시 ALT 복상솔화 HBV DNA 전음솔분별체95．1％화91．8％，HBsAg 정량교기선현저하강（P ＜0．05）；48주시완전병독학응답솔여제4주시 HBV DNA 재량유현저상관성。결론은체잡위항병독안전、유효；제4주시 HBV DNA 재량대48주시완전병독학응답솔유흔호적예측작용。
Objective To evaluate the antiviral efficacy of entecavir and to analyze relevant predictive factors. Methods Sixty-one patients with CHB were enrolled and given entecavir for 48 weeks.ALT,serological indicators and HBV DNA were determined at baseline,4th week,12th week,24th week and 48th week during the treatment.Results At 48th week,rate of ALT normalization was 95.1 %,while rate of undetectable HBV DNA was 91 .8% and HBsAg level was decreased obviously (P <0.05 )when compared with baseline.Complete virological response rate at 48th week was significantly associated with HBV DNA level at 4th week.Conclusions Entecavir is effective and safe for patients with CHB.Virus load at 4th week is a good predictor of complete virological response rate at 48th week.